DOCSLIB.ORG

Désiré Collen, Biotech Pioneer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Désiré Collen, Biotech Pioneer Paul Huybrechts, Frieda Van Wijck Désiré Collen, Biotech Pioneer Paul Huybrechts Frieda Van Wijck Paul Huybrechts (1946) is a former financial journalist with the newspaper De Morgen, and the financial daily De Tijd. He later became managing director of the Publishing Company Tijd, owner of the daily, and chairman of the VFB (Vlaamse Federatie van Beleggers), the Flemish federation of retail investors. He is the author of Hugo’s Heilige Vuur, an extensive biography of the early years of Flemish politician Hugo Schiltz, and of SOS NMBS, a book on the dire situation of NMBS, the Belgian railroad company. He is co-author as well of Naar Grijsland, a book on the financial consequences of an aging population. Frieda Van Wijck (1950) is a former journalist and presenter for VRT – the Dutch-language public radio and television station in Belgium. She worked as a reporter and presenter for the Belgian World Service and hosted political television programs such as Terzake and De Zevende Dag. She interviewed many national and international celebrities and politicians on television for Spraakmakers and presented entertainment programs such as In alle Staten, De Laatste Show and De Klas van Frieda. © LSRP vzw, Paul Huybrechts, Frieda Van Wijck ISBN 978-1-64999-608-4 Translated from: Désiré Collen, Biotechpionier Authors: Paul Huybrechts, Frieda Van Wijck Publisher: LannooCampus Publishers, Leuven, Belgium 2 Table of Contents Foreword ............................................................................................................................................................ 7 PART I: FROM NATURAL T-PA TO RECOMBINANT T-PA .................................... 9 Chapter 1: The making of a researcher ................................................................ 11 An exemplary student....................................................................................................................................... 13 Cristal rather than Stella ................................................................................................................................... 15 Blood for Marc Verstraete ................................................................................................................................ 16 Blood clot, cause or consequence? .................................................................................................................. 17 Doubt persists ................................................................................................................................................... 19 Guido Tytgat’s wake-up call .............................................................................................................................. 21 Chemistry in a turbulent city ............................................................................................................................ 23 Collen contracts hepatitis B .............................................................................................................................. 25 New York disappoints ....................................................................................................................................... 27 With a Viking in Sweden ................................................................................................................................... 28 The lab rather than the hospital ward .............................................................................................................. 30 Military service, but research continues .......................................................................................................... 31 Discovery of α2-antiplasmin ............................................................................................................................. 33 Breeding rabbits ............................................................................................................................................... 36 Chapter 2: The development of t-PA ..................................................................... 39 The experiments of Björn Wiman ..................................................................................................................... 41 Fons Billiau and the melanoma cell line ........................................................................................................... 42 Dick Rijken and Osamu Matsuo ........................................................................................................................ 44 Chapter 3: Enter Genentech .................................................................................. 47 DNA attracts money ......................................................................................................................................... 49 The girl in the pink sweater .............................................................................................................................. 51 Cloning recombinant cDNA of t-PA................................................................................................................... 54 A patient in Rotterdam ..................................................................................................................................... 55 Tests in Saint Louis ............................................................................................................................................ 56 Diane’s empty circles ........................................................................................................................................ 58 Competitors appear .......................................................................................................................................... 59 Chapter 4: The road to confirmation ..................................................................... 61 Recombinant t-PA (rt-PA) tested in Leuven and Boston................................................................................... 63 A first t-PA patient in Leuven ............................................................................................................................ 66 FDA allows rt-PA tests on patients ................................................................................................................... 68 Verstraete mobilizes European cardiologist ..................................................................................................... 69 rt-PA beats streptokinase ................................................................................................................................. 70 3 Chapter 5: The FDA approves rt-PA...................................................................... 73 rt-PA becomes Activase .................................................................................................................................... 75 Fireworks in San Francisco ................................................................................................................................ 77 The failure of the Innovi adventure .................................................................................................................. 78 The biblical manna of the D. Collen Research Foundation ............................................................................... 80 In court in Delaware ......................................................................................................................................... 82 Which is the better therapy? ............................................................................................................................ 83 Roche takes over Genentech ............................................................................................................................ 86 Oxford throws doubts on rt-PA ........................................................................................................................ 87 The final assessment of rt-PA ........................................................................................................................... 88 Still standard for treatment of ischemic stroke ................................................................................................ 89 PART II: THROMBOLYSIS FOR THE POOR ....................................................... 91 Chapter 1: Entrepreneurship with Thromb-X ....................................................... 93 Yakult Honsha and Matsuo open up a new path .............................................................................................. 95 Ireland and the Cayman Islands ........................................................................................................................ 96 Testing on baboons........................................................................................................................................... 98 Envy among professors ................................................................................................................................... 100 Production by Medac...................................................................................................................................... 101 It works in patients ......................................................................................................................................... 102 An unpleasant surprise ..................................................................................................................................
Load more

Recommended publications
  • 8733/21 HVW/Io 1 LIFE.1 Delegations Will Find in Annex a Joint Declaration by Czech Republic, Hungary, Poland, Slovakia, Bulgar
    Council of the European Union Brussels, 12 May 2021 (OR. en) 8733/21 AGRI 218 ENV 305 PESTICIDE 16 PHYTOSAN 17 VETER 37 PECHE 146 MARE 14 ECOFIN 437 RECH 212 SUSTDEV 61 DEVGEN 95 FAO 16 WTO 133 NOTE From: General Secretariat of the Council To: Delegations Subject: Joint Declaration of the Ministers of Agriculture of the Visegrad Group (Czech Republic, Hungary, Poland and Slovakia) and Bulgaria, Croatia and Romania on the opportunities and challenges for farmers stemming from the Farm to Fork strategy - Information from the Polish delegation on behalf of the Bulgarian, Croatian, Czech, Hungarian, Polish, Romanian and Slovakian delegations Delegations will find in Annex a joint declaration by Czech Republic, Hungary, Poland, Slovakia, Bulgaria, Croatia and Romania on the above subject, concerning an item under "Any other business" at the Council (''Agriculture and Fisheries'') on 26-27 May 2021. 8733/21 HVW/io 1 LIFE.1 EN ANNEX Joint declaration of the Ministers of Agriculture of the Visegrad Group (Czech Republic, Hungary, Poland and Slovakia) and Bulgaria, Croatia, Romania, on the opportunities and challenges of agricultural holdings in light of the Farm to Fork Strategy On 21 April 2021 the Polish Presidency of Visegrad Group organized a videoconference of Ministers of Agriculture of the Visegrad Group: (Czech Republic, Hungary, Poland and Slovakia) and Bulgaria, Croatia, Romania and Slovenia (GV4+4). The main topic of the discussion was the opportunities and challenges of agricultural holdings in the GV4 + 4 countries in light of the Farm to Fork Strategy. The Ministers also exchanged views on the Strategic Plans of the Common Agricultural Policy (CAP).
    [Show full text]
  • A Conversation with Eugene Braunwald
    A conversation with Eugene Braunwald Ushma S. Neill J Clin Invest. 2013;123(1):1-2. https://doi.org/10.1172/JCI67778. Conversations with Giants in Medicine Eugene Braunwald (Figure 1) is often called the father of modern cardiology, as he was the first to define the pathophysiology of hypertrophic cardiomyopathy and to demonstrate the salvage of ischemic myocardium following coronary occlusion. The full interview, with many more stories about performing in the opera and his seminal research discoveries, can be seen on the JCI website, http://www.jci.org/kiosk/cgm. JCI: Can you tell us about your path to medical school? Braunwald: I was born in Vienna, Austria, and had an idyllic childhood there with an excellent school, and tutors in English and piano. On March 12, 1938, everything changed because Austria was annexed by Germany. The Nazis came in, and the fury against the Jews played out in a matter of days. It was a very troubling period. We escaped from Austria at the end of July 1938 with a couple of close calls. It was like The Sound of Music — except that there was no music. We ended up in London two days later, literally with just the shirts on our back. When war was declared in September 1939, my brother and I were evacuated to a small village in Northern England. After living with a wonderful family for a couple of months, I got a postcard that our family was going to America. We took the […] Find the latest version: https://jci.me/67778/pdf Conversations with giants in medicine A conversation with Eugene Braunwald Eugene Braunwald (Figure 1) is often carried out in probably 4,000 hospitals in give them relief from severe angina.
    [Show full text]
  • Final Program
    1 General Information SCOPE OF THE CONFERENCE The 12th Joint MMM/Intermag Conference is sponsored jointly by the American Institute of Physics (through Physics Conferences Incorporated) and the Magnetics Society of IEEE. The Conference will be held at the Hyatt Regency Chicago in the heart of Chicago, Illinois, easily accessible from O'Hare and Midway Airports. Members of the international scientific and engineering communities interested in recent developments in funda- mental and applied magnetism are invited to attend the Conference and con- tribute to its technical sessions. Sessions will include invited and contributed papers in oral and poster sessions, invited symposia, a plenary session, and two evening sessions, one of which will be in a tutorial format. The Confer- ence provides an outstanding opportunity for participants to meet their col- leagues and discuss the latest advances in magnetism. Please note that all of the conference details, including web links for registration and hotel reser- vations, are available at the conference website: http://www.magnetism.org CHICAGO Few cities in the world can match the character and culture of Chicago. Here you can find world-class dining, museums and entertainment. Chicago is the largest and most visited city in the Midwest of the United States. The Chicago Convention & Tourism Bureau is dedicated to helping you enjoy your stay in Chicago. On its web site, http://www.choosechicago.com you can experience the city like a local by obtaining the latest information on Chicago attractions such as the Navy Pier and Millennium Park, as well as the numerous outstanding museums and galleries.
    [Show full text]
  • Our Business Enablers Extended 2013 (Incl. CR Performance Discussion)
    Syngenta 01 Our business enablers extended 2013 Our business enablers extended 2013 (incl. CR performance discussion) Corporate Responsibility (CR) is an integral part of everything we do. We are guided by Contents the conviction that value creation depends Research and Development 02 on the successful integration of business, social and environmental performance. People 04 Our CR performance is covered throughout the printed Annual Review, summarized in the Overview 04 Corporate Responsibility information section People retention 05 and explained in further detail in the extended Diversity and inclusion 07 “Our business enablers” section of the Online Employee development 08 Annual Report (www.syngenta.com/ar2013). Reward and recognition 09 Health, safety and wellbeing 09 In this document, we provide the extended “Our business enablers” section with the Manufacturing and procurement 11 detailed information on our CR performance in 2013. Overview 11 Our production and R&D sites 12 Quality management 12 Security management 13 Responsible supply chain 13 Environment 14 Overview 14 Energy efficiency 15 Climate change and GHG emissions 16 Other air emissions 18 Water 19 Wastewater 20 Waste 21 Environmental compliance 22 Responsible agriculture 23 Overview 23 Resource efficiency 25 Product safe use 26 Economic value shared 28 Overview 28 Assured CR performance Economic contribution 29 indicators 2013 Business integrity 30 You can download a document with the Overview 30 assured CR performance indicators from Corporate conduct 31 www.syngenta.com/ar2013, section “Our business enablers”. Animal testing compliance 31 Biotechnology and regulatory compliance 31 About our CR reporting 32 Contact us CR governance 32 Materiality and stakeholder engagement 33 Your feedback is important to us.
    [Show full text]
  • KU LEUVEN Jaarrekening 2018
    KU LEUVEN Jaarrekening 2018 Permanent dossier 1 2 INHOUD DEEL 1 Jaarrekening Tabellen conform het boekhoudbesluit van 21 december 2007 ....................... 4 DEEL 2 Samenvatting van de toegepaste waarderingsregels ........................................................... 34 DEEL 3 Resultatenrekening per afdeling ........................................................................................... 41 WERKING ................................................................................................................. 42 INVESTERINGEN .................................................................................................... 44 SOCIALE VOORZIENINGEN VOOR STUDENTEN ................................................ 46 ONDERZOEKSFONDSEN ...................................................................................... 48 AFDELING IV.1: BIJZONDER ONDERZOEKSFONDS ............................................................... 48 AFDELING IV.2: ANDERE ONDERZOEKSFONDSEN ............................................................... 50 PATRIMONIUM ........................................................................................................ 52 VOOR ORDE .......................................................................................................... 54 DEEL 4 ESR Rapportering 2018........................................................................................................ 58 3 DEEL 1 Jaarrekening Tabellen conform het boekhoudbesluit van 21 december 2007 4 5 Vol 1. bis LIJST VAN DE BESTUURDERS,
    [Show full text]
  • De Vlaams-Nationalistische Partijen En Organisaties Bruno De Wever En Koen De Scheemaeker
    808 Bronnen van privé-instellingen 5.5. Bronnenpublicaties Documents sur la fondation du pcb, in Cahiers marxistes, 1971, speciaal nummer. In de nrs. 2 (p. 43-47), 9 (p. 44-54) en 10 (p. 71-88) van hetzelfde tijdschrift worden eveneens documenten gepubliceerd die betrekking hebben op de ontstaans periode van de kpb. “ Le Drapeau Rouge ” clandestin. Brussel, 1971. De klandestiene “ Roode Vaan ”. Brussel, 1971. Alphonse Bonenfast. Rapport sur la dissidence grippiste (1968), in Cahiers marxistes, 2002, nr. 222. 6. De Vlaams-nationalistische partijen en organisaties Bruno De Wever en Koen De Scheemaeker 6.1. Bibliografie Courrier hebdomadaire du CRISP wijdde talrijke artikels aan Vlaams-nationalis- tische partijen en organisaties na de Tweede Wereldoorlog : 1962, nrs. 148 & 169 ; 1964, nr. 230 ; 1966, nrs. 336 & 345 ; 1973, nrs. 604 & 606 ; 1992, nr. 1356 ; 1993, nrs. 1416-1417, 2002, nr. 1748. De Wever (Br.). Greep naar de macht. Vlaams-nationalisme en Nieuwe Orde. Het VNV 1933-1945. Tielt-Gent, 1994. De Wever (Br.), Vrints (A.). Vlaams-nationalisme. Natievorming, ideologie en politieke stroming, in Sanders (L.), Devos (C.), eds. Politieke ideologieën in Vlaanderen. Antwerpen, 2008. De Wever (Ba.). Het Vlaams-nationalisme na de Tweede Wereldoorlog. Verrij- zenis of herrijzenis ?, in Bijdragen tot de Eigentijdse Geschiedenis, 1997, nr. 3, p. 277-290. De Winter (L.). The Volksunie and the dilemma between policy succes and elec- toral survival in Flanders, in Regionalist Parties in Western Europe. London, 1998, p. 28-50. Nieuwe Encyclopedie van de Vlaamse Beweging. Tielt, 1998 bevat ingangen op alle Vlaams-nationalistische partijen en organisaties, een overzichtsartikel over Vlaams-nationalistische partijen (B.
    [Show full text]
  • Agricultural and Agribusiness Consultants
    THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY Voluntary - Public Date: 10/1/2014 GAIN Report Number: IN4085 India Post: New Delhi Agricultural and Agribusiness Consultants - 2014 Report Categories: Food Processing Ingredients Food Service - Hotel Restaurant Institutional Fresh Fruit Dried Fruit Beverages Exporter Guide Approved By: Jonn P Slette Prepared By: Shubhi Mishra and Dhruv Sood Report Highlights: This report provides a partial list of consultants available for conducting market research and other inquiries into Indian agriculture, agribusiness, food retail, food/agricultural economics, and rural affairs. This list is neither exhaustive nor all-inclusive. Inclusion of any consultant on this list does not constitute an endorsement of that consultant, nor does exclusion of any consultant from this list imply any lack of such endorsement. This list is provided strictly as a courtesy to those who desire information in greater detail than is typically provided in this office’s GAIN reports. General Information: This report provides a partial list of consultants available for conduct of market research and other examinations of Indian agriculture, agribusiness, food retailing, food economy, and rural affairs. Some firms on this list also offer representation services for firms desiring a local presence in the market. Readers of GAIN reports sometimes address to this office inquiries or requests for information that exceed the ability of USDA’s offices in India to fulfill. These inquiries range from requests for detailed research into a specific Indian state’s agriculture sector to requests for in-depth analysis of a specific product.
    [Show full text]
  • Belgian Polities in 1988 Content 1. the Painstaking Forming of The
    Belgian Polities in 1988 Content 1. The painstaking forming of the Martens VIII Cabinet 303 A. The forming of regional governments complicates the making of a national cabinet . 303 B. The information mission of Dehaene 305 C. Dehaene's formation mission . 305 D. Martens VIII wins vote of confidence in Parliament 308 ll. Phase one of the constitutional reform 309 A. The amendment of seven constitutional articles 309 B. The special August 8, 1988 Act. 310 C. The bill on the language privileges . 312 111. The second phase of the constitutional reform 314 A. The new politica! status of the Brussels Region 314 B. The Arbitration Court . 315 C. The regional financing law. 315 D. Consultation and meditation 316 IV. The municipal elections, the government reshuffle and the debt of the larger cities 317 A. The municipal elections, Fourons and municipalities with special language status 317 B. The government reshuffle . 318 C. The debt of the larger cities 318 V. The social and economie policy of the Martens VIII cabinet 319 A. The 1988 and 1989 budgets 319 B. Tax reform 320 C. Labor Relations-Public Service Strikes-Health lnsurance 321 Vl. Foreign Affairs and Defense. 323 A. Foreign Affairs 323 B. Defense . 325 VII. lnternal politica! party developments. 325 Belgian polities in 1988 by Ivan COUTTENIER, Licentiate in Politica) Science During the first four months of 1988, Belgium witnessed the painstaking for­ mation of the Martens VIII center-left Cabinet. In October 1987, the Christian Democratic-Liberal Martens VI Cabinet had been forced to resign over the pe­ rennial Fourons affairs.
    [Show full text]
  • Advances in Cardiovascular Risk Reduction IMPROVING TREATMENT for PATIENTS with DIABETES
    NYU School of Medicine Continuing Medical Education THE IRWIN D. MANDEL Advances in Cardiovascular Risk Reduction IMPROVING TREATMENT FOR PATIENTS WITH DIABETES Thursday, May 9, 2019 New York, NY nyulmc.org/cvriskcme Jointly provided by NYU School of Medicine and the New York State Chapter American College of Physicians (NYACP) SPEAKERS COURSE DIRECTOR Edward A. Fisher, MD, PhD, MPH James A. Underberg, MD Leon H. Charney Professor Clinical Assistant Professor Arthur Z. Schwartzbard, MD of Cardiovascular Medicine of Medicine Associate Professor of Medicine Professor of Cell Biology, Medicine, Director, Clinical Lipid Research Microbiology, and Pediatrics Howard Weintraub, MD Director, Preventive Cardiology Director, Marc and Ruti Bell Clinical Professor of Medicine Fellowship Program Vascular Biology Program Clinical Director, Center for the Center for the Prevention of Co-Director, Center for the Prevention Prevention of Cardiovascular Disease Cardiovascular Disease of Cardiovascular Disease Associate Director, Preventive NYU School of Medicine Cardiology Fellowship Program Lauren H. Golden, MD Clinical Associate COURSE PLANNERS Professor of Medicine GUEST SPEAKERS Director, Center for Diabetes Jeffrey S. Berger, MD and Metabolic Health Paul Ridker, MD Edward A. Fisher, MD, Eugene Braunwald PhD, MPH Ira J. Goldberg, MD Professor of Medicine Harvard Medical School Clarissa and Edgar Bronfman, Jr. Mattia Gilmartin, RN, Senior Physician Professor of Endocrinology Brigham and Women’s Hospital PhD, FAAN Director, Division of Endocrinology, Boston, MA Ira J. Goldberg, MD Diabetes and Metabolism Ana M. Mola, RN, PhD, Dennis A. Goodman, MD Clay F. Semenkovich, MD Irene E. and Michael M. Karl Professor ANP-BC, MAACVPR Clinical Professor of Medicine Chief, Division of Endocrinology, Director, Integrative Medicine Lawrence Phillips, MD Metabolism and Lipid Research NY Chapter American Professor of Medicine and of College of Physicians Sean P.
    [Show full text]
  • Putting the Cartel Before the Horse ...And Farm, Seeds, Soil, Peasants, Etc
    Communiqué www.etcgroup.org September 2013 No. 111 Putting the Cartel before the Horse ...and Farm, Seeds, Soil, Peasants, etc. Who Will Control Agricultural Inputs, 2013? In this Communiqué, ETC Group identifies the major corporate players that control industrial farm inputs. Together with our companion poster, Who will feed us? The industrial food chain or the peasant food web?, ETC Group aims to de-construct the myths surrounding the effectiveness of the industrial food system. Table of contents Introduction: 3 Messages 3 Seeds 6 Commercial Seeds 7 Pesticides and Fertilizers 10 Animal pharma 15 Livestock Genetics 17 Aquaculture Genetics Industry 26 Conclusions and Policy Recommendations 31 Introduction: 3 Messages ETC Group has been monitoring the power and global reach of agro-industrial corporations for several decades – including the increasingly consolidated control of agricultural inputs for the industrial food chain: proprietary seeds and livestock genetics, chemical pesticides and fertilizers and animal pharmaceu- ticals. Collectively, these inputs are the chemical and biological engines that drive industrial agriculture. This update documents the continuing concentration (surprise, surprise), but it also brings us to three conclusions important to both peasant producers and policymakers… 1. Cartels are commonplace. Regulators have lost sight of the well-accepted economic principle that the market is neither free nor healthy whenever 4 companies control more than 50% of sales in any commercial sector. In this report, we show that the 4 firms / 50% line in the sand has been substan- tially surpassed by all but the complex fertilizer sector. Four firms control 58.2% of seeds; 61.9% of agrochemicals; 24.3% of fertilizers; 53.4% of animal pharmaceuticals; and, in livestock genetics, 97% of poultry and two-thirds of swine and cattle research.
    [Show full text]
  • Discord & Consensus
    c Discor Global Dutch: Studies in Low Countries Culture and History onsensus Series Editor: ulrich tiedau DiscorD & Discord and Consensus in the Low Countries, 1700–2000 explores the themes D & of discord and consensus in the Low Countries in the last three centuries. consensus All countries, regions and institutions are ultimately built on a degree of consensus, on a collective commitment to a concept, belief or value system, 1700–2000 TH IN IN THE LOW COUNTRIES, 1700–2000 which is continuously rephrased and reinvented through a narrative of cohesion, and challenged by expressions of discontent and discord. The E history of the Low Countries is characterised by both a striving for consensus L and eruptions of discord, both internally and from external challenges. This OW volume studies the dynamics of this tension through various genres. Based C th on selected papers from the 10 Biennial Conference of the Association OUNTRI for Low Countries Studies at UCL, this interdisciplinary work traces the themes of discord and consensus along broad cultural, linguistic, political and historical lines. This is an expansive collection written by experts from E a range of disciplines including early-modern and contemporary history, art S, history, film, literature and translation from the Low Countries. U G EDIT E JANE FENOULHET LRICH is Professor of Dutch Studies at UCL. Her research RDI QUIST AND QUIST RDI E interests include women’s writing, literary history and disciplinary history. BY D JAN T I GERDI QUIST E is Lecturer in Dutch and Head of Department at UCL’s E DAU F Department of Dutch.
    [Show full text]
  • Wilfried Martens. Deel 2
    BE-A0510_000966_002273_DUT Inventaris van het archief van Wilfried Martens. Deel 2. Van Belgisch premier tot EVP-voorzitter, 1978-2009 (1919) Het Rijksarchief in België Archives de l'État en Belgique Das Staatsarchiv in Belgien State Archives in Belgium This finding aid is written in Dutch. 2 Wilfried Martens. Deel 2 BESCHRIJVING VAN HET ARCHIEF:...................................................................33 Raadpleging en gebruik.................................................................................34 Voorwaarden voor de raadpleging.............................................................34 Voorwaarden voor de reproductie..............................................................35 Fysieke kenmerken en technische vereisten..............................................35 Toegangen..................................................................................................35 Aanwijzingen voor het gebruik...................................................................36 Geschiedenis van archiefvormer en archief...................................................37 Archiefvormer............................................................................................37 Naam......................................................................................................37 Archief........................................................................................................37 Geschiedenis..........................................................................................37 Verwerving.............................................................................................39
    [Show full text]